Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Lung cancer (Amsterdam, Netherlands) | 2007-06-01 | PMID 17368623
Sunaga Noriaki, Tomizawa Yoshio, Yanagitani Noriko and 10 more
Genes: EGFR
